Affinity Asset Advisors LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Affinity Asset Advisors LLC acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 130,000 shares of the company’s stock, valued at approximately $5,018,000. Affinity Asset Advisors LLC owned approximately 0.22% of Protagonist Therapeutics at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new position in shares of Protagonist Therapeutics in the fourth quarter worth $38,000. Covestor Ltd lifted its holdings in Protagonist Therapeutics by 5,200.0% in the fourth quarter. Covestor Ltd now owns 1,643 shares of the company’s stock worth $63,000 after purchasing an additional 1,612 shares during the period. KBC Group NV grew its position in Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company’s stock valued at $81,000 after buying an additional 737 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Protagonist Therapeutics by 10.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock valued at $121,000 after buying an additional 295 shares during the period. Finally, Cibc World Markets Corp bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth about $211,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PTGX. Wedbush reiterated an “outperform” rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, March 28th. Truist Financial lifted their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a “buy” rating in a research report on Tuesday, March 11th. JMP Securities restated a “market outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday, February 7th. BMO Capital Markets lifted their target price on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Finally, The Goldman Sachs Group cut their price target on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, February 24th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $65.44.

Protagonist Therapeutics Trading Up 5.7 %

NASDAQ:PTGX opened at $45.03 on Tuesday. Protagonist Therapeutics, Inc. has a 1-year low of $24.22 and a 1-year high of $60.60. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of 16.93 and a beta of 2.30. The business’s fifty day moving average price is $44.19 and its 200 day moving average price is $42.74.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Friday, February 21st. The company reported $1.98 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. The company had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. Equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Insiders Place Their Bets

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 30,514 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $55.74, for a total value of $1,700,850.36. Following the transaction, the insider now directly owns 83,892 shares of the company’s stock, valued at $4,676,140.08. This represents a 26.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the sale, the director now owns 13,130 shares of the company’s stock, valued at approximately $712,302.50. This represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,776 shares of company stock worth $3,585,010 in the last quarter. 5.40% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.